A syringe is a pump consisting of a plunger that fits tightly in a cylindrical tube. The plunger can be pulled and pushed along inside the tube allowing the syringe to take in and expel a liquid through an orifice at the open end of the tube. The open end can be fitted with a hypodermic needle, a nozzle or tubing.
The internal deposition of cold slurry has many potential clinical benefits. The present invention relates to the delivery of cold slurry to internal tissues and organs as a therapy for a variety of health conditions. For example, cold slurry is delivered at or near adipose tissue, colonic tissue, or abdominal tissue. The cooling effect of the cold slurry on those tissues or others stimulates thermogenesis in brown adipose tissue and increases general metabolic activity. As such, cold slurry therapy is useful to treat obesity, to reduce adipose tissue, and to treat metabolic conditions associated therewith. In another example, cold slurry is delivered at or near internal tissue injured by trauma or disease. The cooling effect of the cold slurry on the injured tissue reduces inflammation which, in turn, reduces pain and promotes healing.
The application of cold slurry is also useful to treat a number of muscular and neurological disorders as well as to treat pain. For example, the cooling effect of cold slurry delivered at or near a nerve reduces the neuronal activity, thereby reducing spasms or pain. The cooling effect of cold slurry on tissue is also used to reduce or remove tissue, for example, to treat fibroadenomas or scar tissue.
One approach to delivering cold slurry is to inject the cold slurry under a patient's skin using a syringe 10 shown in
The syringe 10 further includes a plunger 50 that slides within the cavity 30 between the first end 20 and the second end 25. At one end, facing the first end 20 of the syringe body 15, the plunger 50 includes a stopper 55 for pushing the cold slurry 35. A stem 60 extends from the stopper 55 towards the second end 25 and terminates at a flange 70. In use, to deliver the cold slurry 35 to a target tissue, a clinician pierces the patient's skin with the needle 45 and advances the needle 45 to a location at or near the target tissue. The clinician then pressed down on the syringe flange 70, which in turn delivers the cold slurry 35 from the cavity 30 through the outlet 40 and out the needle 45 to the target tissue.
The cold slurry is preferably kept at a proper treatment temperature. Depending on the tissue being treated, cold slurry temperature ranges from about 10° C. to about −50° C. Cold slurry melts quickly, so temperature must be maintained, especially when multiple injections are used.
A cold slurry syringe according to the invention has enhanced features for delivering a cold slurry into the human body. A syringe of the invention includes a syringe body for holding a volume of cold slurry (or a cool fluid that transitions to a cold slurry), a plunger that slides within the syringe body for ejecting the cold slurry, and a tapered syringe head for delivering an even flow of cold slurry. The taper prevents, or assists in preventing, clogging or phase change of the material in the syringe. An agitator can be added to keep the cold slurry from agglomerating and clogging the cold slurry syringe. The agitator can have many forms such as vibration, rotation, and use of augers. Insulation added around the cold slurry syringe can keep the cold slurry from melting too quickly. A ball screw drive, or other mechanism for controlling content pressure and/or flow from the device, can be added to provide a smooth and consistent application of pressure as the cold slurry is delivered. The cold slurry flow can be enhanced by adding a streamline flow feature that reduces the occurrence of eddies or swirls inside the syringe. This feature helps maintain the composition and consistency of the cold slurry.
One aspect of the invention is a device comprising a syringe body having a first end, a second end, and a longitudinal axis extending through the first and second ends. The syringe body further includes an interior lumen defined by an interior wall of the syringe body. The interior lumen is configured to receive and contain a volume of cold slurry. In some examples, the cold slurry can be made inside the syringe. In such examples, the interior lumen receives a cool fluid where it is cooled down to become a cold slurry. The device further has a plunger that is slideably movable within the interior lumen between the first and second ends along the longitudinal axis. The plunger includes a stopper and a stem extending from the stopper.
The device further has a syringe head extending from the first end of the syringe body along the longitudinal axis. The syringe head includes an inlet defining a first passageway in fluid communication with the interior lumen of the syringe body. The first passageway has a first diameter that is about the same as a diameter of the interior lumen. The syringe head further includes an outlet spaced a predetermined distance from the inlet along the longitudinal axis. The outlet defines a second passageway in fluid communication with the outside to serve as an exit for delivering cold slurry. The second passageway has a second diameter smaller than the first diameter. Extending between the inlet and outlet there is a reducer. The reducer defines a third passageway in fluid communication with the first and second passageways. The third passageway has a third diameter tapering from the first diameter to the second diameter.
The present invention provides a cold slurry syringe with enhanced features for delivering cold slurry into the human body. A cold slurry syringe of the invention includes a syringe body for holding a volume of cold slurry, a plunger that slides within the syringe body for ejecting the cold slurry, and a tapered syringe head for delivering an even flow of cold slurry. An agitator can be added to the cold slurry syringe to keep the cold slurry from agglomerating and clogging the cold slurry syringe. A ball screw drive, or other mechanism for controlling flow of pressure, can be added to the cold slurry syringe to provide a smooth and consistent application of pressure as the cold slurry is delivered. Insulation added around the cold slurry syringe can keep the cold slurry from melting too quickly. The flow of cold slurry can be enhanced by adding a streamline flow feature to the cold slurry syringe that can reduce eddies or swirls from occurring inside the cold slurry syringe. Examples of the aforementioned enhancements and others are now described in greater detail below.
The cold slurry syringe 100 further includes a plunger 120 at least partially disposed within the interior lumen 130. The plunger 120 is configured to move in and out of the syringe body 110 between the first end 112 and the second end 114. The plunger 120 includes a stopper 122, a plunger head 124, and a stem 126 extending between the stopper 122 and the plunger head 124 along the longitudinal axis LA. The stopper 122 and the plunger head 124 are spaced apart at a predetermined distance.
The syringe body 110 can be made of any type of biocompatible pharmacologically inert material suitable for use in containing and supplying fluids to be provided within a human body. Exemplary materials for the syringe body 110 include plastic, such as polyethylene or polypropylene, and glass. The cold slurry syringe 100 can be any size that is suitable to hold one or more aliquots of cold slurry for delivery to the target tissue. The volume capacity of the cold slurry syringe 100 is typically between 1 ml and 60 ml, although capacity outside of those volumes is also contemplated.
The cold slurry syringe 100 further includes a syringe head 155 extending from the first end 112 of the syringe body 110 along the longitudinal axis LA. The syringe head 155 has an inlet 160 and an outlet 165 spaced a predetermined distance from the inlet 160 along the longitudinal axis LA. The inlet 160 defines a first passageway 170 in fluid communication with the interior lumen 130. The interior lumen 130 has a diameter D and the first passageway 170 has a first diameter D1 that is about the same as the interior lumen diameter D. The outlet 165 defines a second passageway 175 in fluid communication with the outside environment and serves as an exit for delivering the cold slurry. The second passageway 175 has a second diameter D2 that is smaller than the first diameter D1.
Extending between the inlet 160 and outlet 165, there is a reducer 180 defining a third passageway 185 in fluid communication with the first passageway 170 and the second passageway 175. The third passageway 185 has a third diameter that tapers from the first diameter D1 to the second diameter D2. This arrangement of passageways provides a smooth transition that allows the cold slurry to flow evenly from the interior lumen 130 through the inlet 160 and out the outlet 165. Reducing turbulence in the cold slurry flow can reduce the possibility that ice particles making up the cold slurry will aggregate and clog the cold slurry syringe 100.
The configuration and geometry of the syringe head 155 can be changed to alter the flow characteristics of the cold slurry. For example,
The syringe head 155 can include features for improving the flow of cold slurry. For example in
The cold slurry syringe 100 also includes at least one needle 140 (not shown) extending from the outlet 165. The needle can have a thickness between 7 gauge and 34 gauge; and can have a length between ¼″ and 10″, such as about ¼″, ½″, 1″, 2″, 3″, 4″, 5″, 6″, 7″, 8″, 9″, or 10″. Preferably, the needle is a hypodermic needle. Exemplary needle materials include, but are not limited to, stainless steel and carbon steel, with or without nickel plating.
In a convenient example, the outlet 165 is configured to receive and engage the needle. For example, the outlet 165 of the second passageway 175 can have threads to receive the needle, or the outlet 165 and the needle can be Luer lock connectors that twist together to make a Luer lock connection. In another example, the outlet 165 is a slip tip onto which the needle is connected. A cold slurry syringe with a slip tip outlet can be connected to tubing or other flexible conduit. In this case, cold slurry is delivered through the tubing.
In order for cold slurry to pass through the needle without clogging, the largest cross-section of the ice particles must be smaller than the internal diameter of the needle and second diameter D2 of the second passageway 175. More particularly, the second diameter D2 is at least 5% larger than a largest cross-section of the ice particles. For example, the largest cross section can be less than about 95% of the internal diameter, less than about 85% of the internal diameter, less than about 75% of the internal diameter, less than about 65% of the internal diameter, less than about 55%, and preferably about 50% of the internal diameter. Exemplary ice particle sizes for various internal diameters, as disclosed in International Patent Application No. PCT/US2015/047292, are provided below in Table 1. It is to be understood that these particles sizes are only meant to be exemplary and not for limitation.
Returning back to the cold slurry syringe 100, the plunger 120, including the stopper 122 and the stem 126, can be any type of biocompatible, pharmacologically inert material suitable for coming in contact with sterile substances to be provided within a human body. Exemplary materials for the plunger 120 include plastic, such as polyethylene or polypropylene, and glass. With respect to the stopper 122, a portion or all of the stopper 122 can be a rubber material, such that a seal is formed between the sides of the stopper 122 and the interior wall of the syringe body 110. The rubber material can be any rubber suitable for coming in contact with sterile substances to be provided to the human body, such as natural rubber latex or a synthetic rubber.
To keep ice particles making up the cold slurry from aggregating, as the cold slurry is contained within a cold slurry syringe awaiting delivery, the cold slurry can be agitated.
As shown, the fins 260 extend out from the hub 255 along a plane that intersects longitudinal axis LA at an angle forming a spiral (or helical) pattern. Alternatively, the fins can extend out from the hub along a plane wherein one dimension of the plane is defined by the longitudinal axis. The agitator 250 can be made out of any material that is suitable for contact with sterile compositions to be delivered to the human body, including those exemplary materials previously provided with respect to the syringe body 110, plunger 120, and needle of
The agitator 250 includes a shaft 275 extending from the hub 255 and through a central bore 280 of the plunger 220. Rotating the shaft 275 turns the agitator 250, which in turn causes cold slurry to flow within the interior lumen 230 in multiple directions, as shown in
In another example, rotation of the agitator 250 is aided by the use of a motor 285. The motor 285 can be drivingly coupled to the cold slurry syringe 200 in any number of ways. For example, the motor 285 is directly coupled to the shaft 275, as shown in
The agitator 250 can have a number of different configurations. For example,
Referring back to
The syringe 300 further includes a plunger 320 partially disposed within an interior lumen 307 containing a volume of cold slurry. The plunger 320 has a through bore 322 for receiving the screw 315 allowing the plunger 320 to rotate about the screw 315. The plunger 320 further includes a stopper 325 at one end and a plunger head 330 at an opposing end. A stem 335 extends between the stopper 325 and the plunger head 330 separating the two by a distance. The stem 335 further includes a nut 340 for engaging the screw threads 317. Rotating the plunger head 330 in a first direction moves the stopper 325 from the second end 310 to the first end. This in turn, pushes the cold slurry out of the interior lumen 307 and delivers the cold slurry to a target tissue. Rotating the plunger head 330 in a second direction moves the stopper 325 from the first end to the second end 310. This motion can be used to draw cold slurry into the interior lumen 307 from, for example, a cold slurry generator (an example of which is described in U.S. Provisional Application 62/416,484, which is incorporated herein in its entirety).
The cold slurry syringe 350 further includes a plunger 370 partially disposed within an interior lumen 357 containing a volume of cold slurry. The plunger 370 includes a stopper 375 at one end and a plunger head 380 at an opposing end. A screw 385 extends between the stopper 375 and the plunger head 380 separating the two by a distance. The screw 385 further includes threads 387 for engaging the nut 390, which is fixed to the second end 360 of the syringe body 355. Rotating the plunger head 380 in a first direction moves the stopper 375 from the second end 360 to the first end. This in turn, pushes the cold slurry out of the interior lumen 357 and delivers the cold slurry to a target tissue. Rotating the plunger head 380 in a second direction moves the stopper 375 from the first end to the second end 360. This motion can be used to draw cold slurry into the interior lumen 357 from, for example, a cold slurry generator (an example of which is described in U.S. Provisional Application 62/416,484, which is incorporated herein in its entirety). Some examples of the cold slurry syringe 350 have a motor drivingly coupled to the plunger head 380, for example, by way of gears, belt and pulley or rack and pinion. The motor drives the head in the first direction to inject the cold slurry and drives the head on the second direction to withdraw the cold slurry. The motor, in turn, can be operable coupled to an electronic controller. Advantageously, with such a controller cold slurry can be injected or withdraw in an automated, autonomous or regulated fashion. The motor can be electrical DC or AC motor. Example motors include rotational and vibrational motors.
As shown in
Another example of the cold slurry syringe includes a hydraulic piston for controlling the rate at which the cold slurry syringe is pressed and the cold slurry is ejected. The hydraulic piston is coupled to the plunger in order to maintain a constant and consistent pressure on the plunger throughout the closed system while plunging and delivering the cold slurry. In this mechanism, the hydraulic piston is mounted on top of the plunger, which with mechanical force, acts on a small cross-sectional area, displacing an incompressible fluid and displacing an equal volume of slurry at a constant rate from the syringe body. This process is performed in order to control possible changes in phase, temperature, and/or pressure on the slurry.
In general, to limit heat from transferring from the environment surrounding the cold slurry syringe to the cold slurry and melting the cold slurry, the cold slurry syringe can be surrounded in insulation. In one embodiment according to the present invention shown in
As shown in
In a convenient example, the insulation 400 is an insulation sleeve for receiving the cold slurry syringe 100. The insulation sleeve can have an open end through which the cold slurry syringe 100 is loaded. A removable cap can further be provided at the open end to allow for insertion and subsequent enclosure of the cold slurry syringe 100 within the insulation sleeve. In another example, the insulation sleeve is of a clamshell design with two halves.
The insulation 400 can be made out of fiberglass insulation, foam insulation, gel insulation, and aerogel insulation, just to name a few examples. The insulation 400 can also be rigid insulation so that when pressure is exerted on the cold slurry syringe (e.g., when delivering cold slurry), the syringe body does not expand or change shape. Similar to the components of the cold slurry syringe, the insulation 400 can also be made out of any material that is biocompatible and pharmacologically inert.
A streamline flow feature can be used to maintain velocity, pressure, and other properties of cold slurry flow from when the cold slurry is generated to when the cold slurry is injected.
The passageway 520 extends along a longitudinal axis LA between the first end 510 and the second end 515 with a plane of the passageway 520 intersecting the longitudinal axis LA at an angle forming a spiral (or helical) pattern. Because of this arrangement, cold slurry can flow throw through the streamline flow feature 500 without turbulence, in parallel layers with no disruption between the layers, and with no cross-currents perpendicular to the flow direction. The streamline flow feature 500 can also reduce the occurrence of eddies or swirls.
Cold slurry moves through the streamline flow feature 500 as a laminar flow allowing ice particles to move parallel to the passageway surface. This can help maintain cold slurry composition (e.g. ice content) from when the cold slurry is generated to when the cold slurry is injected in a patient. It can further help reduce agglomeration and/or inconsistency in cold slurry composition.
The cold slurry syringes 100, 200, 300, 350, and 530 described above can be used to deliver a wide variety of cold slurries. For example, the cold slurry can have a temperature of about 10° C., 7° C., 5° C., 4° C., 3° C., 2° C., 1° C., 0° C., −1° C., −2° C., −3° C., −4° C., −5° C., −10° C., −15° C., −20° C., −30° C., −40° C., and −50° C. The cold slurry can contain between about 0.1% and about 75% ice by weight, between about 0.1% and 1% ice by weight, between about 1% and 10% ice by weight, between about 10% and about 20% ice by weight, between about 20% and about 30% ice by weight, between about 30% and about 40% ice by weight, between about 40% and about 50% ice by weight, between about 50% and about 60% ice by weight, between about 60% and about 70% ice by weight, and greater than about 50% ice by weight. (The proportions of ice by volume are slightly higher due to the densities of solid and liquid water.) The cold slurry can include ice particles having a largest cross-sectional dimension that is less than about 2 mm, about 1.75 mm, about 1.5 mm, about 1.25 mm, about 1 mm, about 0.9 mm, about 0.8 mm, about 0.7 mm, about 0.6 mm, about 0.5 mm, about 0.4 mm, about 0.3 mm, about 0.2 mm, or about 0.1 mm. Other exemplary cold slurry compositions, slurry temperatures, and cross-sectional dimensions of ice particles are provided in PCT/US2015/047292, which is incorporated herein in its entirety. It is to be understood that an advantage of the cold slurry in accordance with the present invention is that the composition of the cold slurry is suitable to delivery to tissues within the body, such that the slurry can be delivered to a tissue within the body of a patient and remain within the body (e.g. no removal of the slurry is necessary after cooling has been effected).
While the present invention has been described in conjunction with certain preferred embodiments, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and other alterations to the apparatuses and methods set forth herein.
The present application is a continuation application of U.S. patent application Ser. No. 15/682,234, filed Aug. 21, 2017, for which a patent was issued on Dec. 10, 2019, having U.S. Pat. No. 10,500,342, the contents of which are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3373906 | Hart et al. | Mar 1968 | A |
3767085 | Cannon | Oct 1973 | A |
3893834 | Armstrong | Jul 1975 | A |
4363329 | Raitto | Dec 1982 | A |
4619678 | Rubin | Oct 1986 | A |
4966601 | Draenert | Oct 1990 | A |
4983045 | Taniguchi | Jan 1991 | A |
4986079 | Koseki et al. | Jan 1991 | A |
5143063 | Fellner | Sep 1992 | A |
5304128 | Haber et al. | Apr 1994 | A |
5445523 | Fischer et al. | Aug 1995 | A |
5507790 | Weiss | Apr 1996 | A |
5769879 | Richards et al. | Jun 1998 | A |
6032675 | Rubinsky | Mar 2000 | A |
6041787 | Rubinsky | Mar 2000 | A |
6067803 | Wolsey et al. | May 2000 | A |
6244052 | Kasza | Jun 2001 | B1 |
6300130 | Toner et al. | Oct 2001 | B1 |
6324863 | Henry | Dec 2001 | B1 |
6334328 | Brill | Jan 2002 | B1 |
6403376 | Toner et al. | Jun 2002 | B1 |
6413444 | Kasza | Jul 2002 | B1 |
6430957 | Inada et al. | Aug 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6475212 | Dobak, III et al. | Nov 2002 | B2 |
6547811 | Becker et al. | Apr 2003 | B1 |
6575930 | Trombley, III et al. | Jun 2003 | B1 |
6673607 | Toner et al. | Jan 2004 | B2 |
6849072 | Lee et al. | Feb 2005 | B2 |
6962601 | Becker et al. | Nov 2005 | B2 |
7118591 | Frank et al. | Oct 2006 | B2 |
7276051 | Henley et al. | Oct 2007 | B1 |
7367341 | Anderson et al. | May 2008 | B2 |
7389653 | Kasza et al. | Jun 2008 | B2 |
7422601 | Becker et al. | Sep 2008 | B2 |
7507234 | Utley et al. | Mar 2009 | B2 |
7588547 | Deem et al. | Sep 2009 | B2 |
7603868 | Sveinsson | Oct 2009 | B2 |
7681411 | DiLorenzo | Mar 2010 | B2 |
7713266 | Elkins et al. | May 2010 | B2 |
7854754 | Ting et al. | Dec 2010 | B2 |
8117854 | Lampe et al. | Feb 2012 | B2 |
8192474 | Levinson | Jun 2012 | B2 |
8275442 | Allison | Sep 2012 | B2 |
8285390 | Levinson et al. | Oct 2012 | B2 |
8298216 | Burger et al. | Oct 2012 | B2 |
8308681 | Slocum et al. | Nov 2012 | B2 |
8337539 | Ting et al. | Dec 2012 | B2 |
8505315 | Kasza et al. | Aug 2013 | B2 |
8523927 | Levinson et al. | Sep 2013 | B2 |
8535275 | Salzman | Sep 2013 | B2 |
8603073 | Allison | Dec 2013 | B2 |
8608696 | DiMeo et al. | Dec 2013 | B1 |
8676338 | Levinson | Mar 2014 | B2 |
8702774 | Baker et al. | Apr 2014 | B2 |
8808241 | DiMeo et al. | Aug 2014 | B2 |
8840608 | Anderson et al. | Sep 2014 | B2 |
8936577 | Lee | Jan 2015 | B2 |
8974451 | Smith | Mar 2015 | B2 |
9016925 | Faccioli | Apr 2015 | B2 |
9044212 | LePivert | Jun 2015 | B2 |
9078634 | Gonzales et al. | Jul 2015 | B2 |
9132031 | Levinson et al. | Sep 2015 | B2 |
9314368 | Allison et al. | Apr 2016 | B2 |
9345526 | Elkins et al. | May 2016 | B2 |
9375345 | Levinson et al. | Jun 2016 | B2 |
9398930 | Leung et al. | Jul 2016 | B2 |
9408745 | Levinson et al. | Aug 2016 | B2 |
9522031 | Anderson et al. | Dec 2016 | B2 |
9545523 | Nanda | Jan 2017 | B2 |
9585687 | Tenenbaum et al. | Mar 2017 | B2 |
9649220 | Anderson et al. | May 2017 | B2 |
9655770 | Levinson et al. | May 2017 | B2 |
9656056 | Boyden et al. | May 2017 | B2 |
9980765 | Avram et al. | May 2018 | B2 |
10174985 | Arnitz et al. | Jan 2019 | B2 |
10406021 | Wu et al. | Sep 2019 | B2 |
10500342 | Velis | Dec 2019 | B2 |
20010005338 | Muhlbauer et al. | Jun 2001 | A1 |
20020107199 | Walker | Aug 2002 | A1 |
20030012079 | Coffeen et al. | Jan 2003 | A1 |
20030032996 | Hallman | Feb 2003 | A1 |
20030074903 | Upadhye et al. | Apr 2003 | A1 |
20030171715 | Hommann et al. | Sep 2003 | A1 |
20030220674 | Anderson et al. | Nov 2003 | A1 |
20040073280 | Dae et al. | Apr 2004 | A1 |
20040092883 | Casey et al. | May 2004 | A1 |
20040199115 | Rosenman | Oct 2004 | A1 |
20040220559 | Kramer et al. | Nov 2004 | A1 |
20050203598 | Becker et al. | Sep 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20060036302 | Kasza et al. | Feb 2006 | A1 |
20060161232 | Kasza et al. | Jul 2006 | A1 |
20060190066 | Worthen | Aug 2006 | A1 |
20070010861 | Anderson et al. | Jan 2007 | A1 |
20070056313 | Kasza et al. | Mar 2007 | A1 |
20070106247 | Burnett et al. | May 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20080045880 | Kjeken et al. | Feb 2008 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080161772 | Nayak et al. | Jul 2008 | A1 |
20080195114 | Murphy | Aug 2008 | A1 |
20080236186 | Kasza et al. | Oct 2008 | A1 |
20080287839 | Rosen et al. | Nov 2008 | A1 |
20080300540 | Lewis | Dec 2008 | A1 |
20090012497 | Uber, III et al. | Jan 2009 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090030366 | Hochman | Jan 2009 | A1 |
20090071829 | O'Banion et al. | Mar 2009 | A1 |
20090118722 | Ebbers et al. | May 2009 | A1 |
20090125087 | Becker et al. | May 2009 | A1 |
20090149929 | Levinson et al. | Jun 2009 | A1 |
20090255276 | Kasza et al. | Oct 2009 | A1 |
20090270814 | Masi et al. | Oct 2009 | A1 |
20100036295 | Altshuler et al. | Feb 2010 | A1 |
20100081971 | Allison | Apr 2010 | A1 |
20100152824 | Allison | Jun 2010 | A1 |
20100152880 | Boyden et al. | Jun 2010 | A1 |
20100249753 | Gaisser et al. | Sep 2010 | A1 |
20100274184 | Chun | Oct 2010 | A1 |
20100280582 | Baker et al. | Nov 2010 | A1 |
20100308257 | Lampe et al. | Dec 2010 | A1 |
20100312202 | Henley et al. | Dec 2010 | A1 |
20110066216 | Ting et al. | Mar 2011 | A1 |
20110190751 | Ingle et al. | Aug 2011 | A1 |
20110238050 | Allison et al. | Sep 2011 | A1 |
20110238051 | Levinson et al. | Sep 2011 | A1 |
20110300079 | Martens et al. | Dec 2011 | A1 |
20120000217 | Gudnason | Jan 2012 | A1 |
20120022518 | Levinson | Jan 2012 | A1 |
20120055187 | Raines et al. | Mar 2012 | A1 |
20120101478 | Stroumpoulis | Apr 2012 | A1 |
20120203312 | Batzer et al. | Aug 2012 | A1 |
20120239123 | Weber et al. | Sep 2012 | A1 |
20120289761 | Boyden et al. | Nov 2012 | A1 |
20130066309 | Levinson | Mar 2013 | A1 |
20130079684 | Rosen et al. | Mar 2013 | A1 |
20130116758 | Levinson et al. | May 2013 | A1 |
20130116759 | Levinson et al. | May 2013 | A1 |
20130158440 | Allison | Jun 2013 | A1 |
20130158636 | Ting et al. | Jun 2013 | A1 |
20130190744 | Avram et al. | Jul 2013 | A1 |
20130245731 | Allison | Sep 2013 | A1 |
20130253496 | Anderson et al. | Sep 2013 | A1 |
20130319080 | Sezaki et al. | Dec 2013 | A1 |
20140005760 | Levinson et al. | Jan 2014 | A1 |
20140067025 | Levinson et al. | Mar 2014 | A1 |
20140091113 | Brewster et al. | Apr 2014 | A1 |
20140200511 | Boyden et al. | Jul 2014 | A1 |
20140257443 | Baker et al. | Sep 2014 | A1 |
20140277219 | Nanda | Sep 2014 | A1 |
20140277302 | Weber et al. | Sep 2014 | A1 |
20140303608 | Taghizadeh | Oct 2014 | A1 |
20140303696 | Anderson et al. | Oct 2014 | A1 |
20140303697 | Anderson et al. | Oct 2014 | A1 |
20140316393 | Levinson | Oct 2014 | A1 |
20140358079 | Fischell et al. | Dec 2014 | A1 |
20140378937 | Anderson et al. | Dec 2014 | A1 |
20150080769 | Lotsch | Mar 2015 | A1 |
20150090769 | Lotsch | Mar 2015 | A1 |
20150112195 | Berger et al. | Apr 2015 | A1 |
20150141916 | Albrecht et al. | May 2015 | A1 |
20150216816 | O'Neil et al. | Aug 2015 | A1 |
20150297246 | Patel et al. | Oct 2015 | A1 |
20150320938 | King et al. | Nov 2015 | A1 |
20150328077 | Levinson | Nov 2015 | A1 |
20150328405 | Metzner | Nov 2015 | A1 |
20150342780 | Levinson et al. | Dec 2015 | A1 |
20150343156 | Fischell et al. | Dec 2015 | A1 |
20160051401 | Yee et al. | Feb 2016 | A1 |
20160058956 | Cohn et al. | Mar 2016 | A1 |
20160081974 | Lee et al. | Mar 2016 | A1 |
20160089550 | DeBenedictis et al. | Mar 2016 | A1 |
20160112195 | Jochheim et al. | Apr 2016 | A1 |
20160128767 | Azamian et al. | May 2016 | A1 |
20160175141 | Wu et al. | Jun 2016 | A1 |
20160184568 | Harris et al. | Jun 2016 | A1 |
20160242661 | Fischell et al. | Aug 2016 | A1 |
20160317621 | Bright | Nov 2016 | A1 |
20160354137 | Fischell et al. | Dec 2016 | A1 |
20160354237 | Gonzales et al. | Dec 2016 | A1 |
20170035603 | Kammer et al. | Feb 2017 | A1 |
20170051353 | Eng | Feb 2017 | A1 |
20170105869 | Frangineas, Jr. | Apr 2017 | A1 |
20170136237 | Eckhouse et al. | May 2017 | A1 |
20170143538 | Lee et al. | May 2017 | A1 |
20170164965 | Chang et al. | Jun 2017 | A1 |
20170202613 | Pellegrino et al. | Jul 2017 | A1 |
20170246032 | Gonzales et al. | Aug 2017 | A1 |
20170274011 | Garibyan | Sep 2017 | A1 |
20170274078 | Garibyan et al. | Sep 2017 | A1 |
20170325992 | DeBenedictis et al. | Nov 2017 | A1 |
20180008500 | Anderson et al. | Jan 2018 | A1 |
20180116868 | Velis | May 2018 | A1 |
20180140514 | Velis et al. | May 2018 | A1 |
20180289537 | Velis | Oct 2018 | A1 |
20180289538 | Velis | Oct 2018 | A1 |
20180311079 | Garibyan et al. | Nov 2018 | A1 |
20190053939 | Garibyan et al. | Feb 2019 | A1 |
20190054242 | Velis | Feb 2019 | A1 |
20200046552 | Velis et al. | Feb 2020 | A1 |
20200113627 | Alas et al. | Apr 2020 | A1 |
20200114041 | Alas et al. | Apr 2020 | A1 |
Number | Date | Country |
---|---|---|
102307545 | Jan 2012 | CN |
103110473 | May 2013 | CN |
105640706 | Jun 2016 | CN |
0418979 | Mar 1991 | EP |
0 445 951 | Sep 1991 | EP |
2 421 545 | Sep 2013 | ES |
2 338 428 | Dec 1999 | GB |
2008-529663 | Aug 2008 | JP |
2006086479 | Aug 2006 | WO |
2009086399 | Jul 2009 | WO |
2009089090 | Jul 2009 | WO |
2013113970 | Aug 2013 | WO |
2016033380 | Mar 2016 | WO |
2016033384 | Mar 2016 | WO |
2016054165 | Apr 2016 | WO |
2016090175 | Jun 2016 | WO |
WO 2017147367 | Mar 2017 | WO |
2017147367 | Aug 2017 | WO |
WO 2017147367 | Aug 2017 | WO |
2017196548 | Nov 2017 | WO |
2018187573 | Oct 2018 | WO |
Entry |
---|
Ash, 2003, Chronic peritoneal dialysis catheters: overview of design, placement, and removal procedures, Int Nephrol Dialysis 16(4):323-34. |
Brink, 2008, Abdominoplasty with direct resection of deep fat, Plast Reconstructive Surg 123(5):1597-1603. |
Ding, 2008, The association between non-subcutaneous adiposity and calcified coronary plaque: A substudy of the multi-ethnic study of atherosclerosis, Am J Clin Nutr 88(3):645-650. |
Esposito, 2016, Do you know this syndrom? Type 2 benign symmetric lipomatos (Launois-Bensaude), Brazilian Annals of Dermatology 91:841. |
Fox, 2007, Abdominal visceral and subcutaneous adipose tissue compartments—association with metabolic risk factors in the Framingham heart study, Circulation 116:39-48. |
Garaulet, 2006, Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans, Int J Obes 30(6):899-905. |
Gentile, 2016, Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are we Sure Everything is Clear?, Diabetes Therapy 7. |
Gradinger, 2005, Abdominoplasty, Chapter 83, pp. 2935-3026, in The art of aesthetic surgery: principles & techniques, Nahai, Ed., Quality Med Pub, St. Louis Mo. (92 pages). |
International Search Report and Written Opinion dated May 15, 2018, for PCT/US17/59947, filed Nov. 3, 2017 (8 pages). |
International Search Report and Written Opinion dated Apr. 12, 2011, for PCT/US11/24766, filed Feb. 14, 2011 (11 pages). |
Kanamori, 2015, A case of an 8-year-old boy who was strongly suspected of suffering from familial angiolipomatosis, J Pediatric Surg 3. |
Kosseifi, 2010, Dercum's Disease: An Unusual Presentation, Pain Medicine 11:1432. |
Laven, 2006, A pilot study of ice-slurry application for inducing laparoscopic renal hypothermia, BJU Int 99:166-70. |
Laverson, 2006, Improving abdominoplasty results: reconstruction of the linea alba sulcus by direct excision, Aesthetic Surg J 26:682-6. |
Lv, 2017, A review of the postoperative lymphatic leakage, Oncotarget 8:69069. |
Popescu, 2014, Proteus Syndrome: a difficult diagnosis and management plan, J Med and Life 7:1. |
Stevens, 2014, Does cryolipolysis lead to skin tightening? A first report of cryodermadstringo, Aesth Surg J 34(6): NP32-NP34. |
Yamamoto, 2010, Adipose depots possess unique developmental gene signatures, Obesity 18(5):872-78. |
Extended European Search Report dated Aug. 28, 2020 in European Application No. 17868153.2. |
Written Opinion dated Jul. 1, 2020 in Singapore Application No. 11201903946S. |
International Preliminary Report on Patentability dated Aug. 21, 2012, for International application No. PCT/US2011/024766, filed Feb. 14, 2011 (8 pages). |
Office Action dated Mar. 1, 2021 in Chinese Application No. 2017800786800, with English translation. |
Int Search Report & Written Opinion dated Aug. 29, 2018 for PCT/US2018/026273 (15 pages). |
Int Search Report & Written Opinion dated Dec. 11, 2019 for International Application No. PCT/US2019/054828. |
Int Search Report & Written Opinion dated Dec. 23, 2019, for PCT/US19/54834, filed Oct. 4, 2019 (10 pages). |
Int Search Report & Written Opinion dated Feb. 11, 2020, for PCT/US19/55633, filed Oct. 10, 2019 (12 pages). |
Int Search Report & Written Opinion dated Jan. 2, 2020, for PCT/US19/55605, filed Oct. 10, 2019 (9 pages). |
Int Search Report & Written Opinion dated Jun. 11, 2018, for PCT/US2018/026260, filed Apr. 5, 2018 (6 pages). |
Int Search Report & Written Opinion dated May 7, 2018, for PCT/US18/20387, filed Mar. 1, 2018 (7 pages). |
Number | Date | Country | |
---|---|---|---|
20200086054 A1 | Mar 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15682234 | Aug 2017 | US |
Child | 16694346 | US |